Immunogenomic landscape of gynecologic carcinosarcoma.
Adult
Aged
Aged, 80 and over
Carcinosarcoma
/ genetics
Cohort Studies
Computational Biology
Female
Genetic Heterogeneity
Humans
Lymphocytes, Tumor-Infiltrating
Middle Aged
Mutation
Ovarian Neoplasms
/ genetics
Ovary
/ immunology
Prognosis
RNA-Seq
Receptors, Antigen, T-Cell
/ genetics
Tumor Microenvironment
/ genetics
Uterine Neoplasms
/ genetics
Uterus
/ immunology
Exome Sequencing
Journal
Gynecologic oncology
ISSN: 1095-6859
Titre abrégé: Gynecol Oncol
Pays: United States
ID NLM: 0365304
Informations de publication
Date de publication:
02 2021
02 2021
Historique:
received:
10
09
2020
accepted:
26
11
2020
pubmed:
11
12
2020
medline:
1
7
2021
entrez:
10
12
2020
Statut:
ppublish
Résumé
Carcinosarcoma (CS) of the uterus or ovary is a rare, biphasic tumor comprising epithelial and mesenchymal elements, and exhibits more aggressive clinical features than its carcinoma counterpart. Four molecular subtypes of CS were recently established based on genomic aberration profiles (POLE, MSI, CNH, and CNL) and shown to be associated with multiple clinicopathological parameters, including patient outcomes. However, the role of the immune microenvironment in CS remains unclear. Here, we investigated the influence of the immune cells that infiltrate CS to better understand the immunological status of gynecological CS. Tumor immune microenvironmental analyses on CS samples were performed using immune cell profiling with RNA-seq, transcriptomic subtyping with microenvironmental genes, and T-cell receptor repertoire assay. Carcinoma and sarcoma elements from CS samples were also assessed separately. Relying on estimations of tumor-infiltrating cell types from RNA-seq data, POLE and MSI (hypermutator) tumors showed an enrichment of M1 macrophages, plasma cells and CD8 Tumor immune microenvironmental analyses could offer potential clinical utility in the stratification of gynecological CS above classification by genomic aberration subtype alone.
Identifiants
pubmed: 33298310
pii: S0090-8258(20)34158-5
doi: 10.1016/j.ygyno.2020.11.030
pii:
doi:
Substances chimiques
Receptors, Antigen, T-Cell
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
547-556Informations de copyright
Copyright © 2020 Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest The authors declare no competing interests.